A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer.
Recruiting now
Conditions studied: Endometrium Cancer
In brief
Prediction of preoperative endometrial biopsy: the evolution from hyperplasia to cancer, the prognosis and the risk of recurrence. Intelligence methods artificial risk will be used to redefine the current risk classes including our profile immuno-mutational to provide a more precise characterization and closer to the real prognosis of the patient.
Key facts
- Study ID
- NCT06841653
- Run by
- Regina Elena Cancer Institute
- People needed
- 40
- Starts
- 2024-06-20
- Expected to finish
- 2026-06-20
- Last updated by the study team
- 2025-02-24
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Age > 18 years;
- Histological diagnosis of endometrial hyperplasia, endometrioid adenocarcinoma of the endometrium, healthy endometrium in patients undergoing total hysterectomy for benign extra-endometrial disease;
- Written informed consent (to the study and data processing), for the party's patients only prospective and/or in follow-up) For the retrospective cohort: availability of samples adequately stored at the biobank of the Institute and availability of data relating to follow-up (at least 2 years)
You may not qualify if…
- All exclusion criteria adopted in the surgical protocols will be applied to the study. In particular:
- Comorbidities not controlled with adequate medical therapy;
- Infections of the endometrial cavity (pyometra);
- Synchronous cancer;
- Neoadjuvant treatments;
- Previous radiotherapy treatments of the pelvic region;
- Hormone therapies.
Where it is running
- IRCCS National Cancer Institute "Regina Elena" — Rome, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.